Maine’s medical cannabis market will not implement testing for contaminants this year, following state lawmakers’ decision to carry over a bill aimed at introducing such requirements. This marks another victory for medical cannabis providers in the state, who have long opposed mandatory testing, arguing it could jeopardize their businesses and raise product prices.
Currently, Maine is unique among states as it does not require testing of medical cannabis, unlike its recreational cannabis market, which mandates both contaminant testing and potency limits. The Office of Cannabis Policy proposed two bills, LD 104 and LD 1847, which would have aligned medical cannabis regulations with recreational standards. LD 104, sponsored by Rep. Marc Malon, sought to enforce seed-to-sale tracking and testing for chemicals, mold, and heavy metals. LD 1847, sponsored by Rep. Anne Graham, included similar requirements while also proposing potency caps on edibles.
Despite strong advocacy from public health officials for the testing measures, both bills faced significant pushback from industry stakeholders. Jennifer Belcher, president of the Maine Cannabis Union, expressed relief that the bills did not advance this session. She warned that if passed, they could dismantle the medical program. Belcher acknowledged the committee’s willingness to consider industry concerns and looked forward to negotiating further before the next legislative session.
Rep. Graham emphasized the importance of ensuring safe cannabis products for patients but recognized the complexity of the issue, noting that the current regulatory framework requires substantial refinement.
The push for testing was partly fueled by a 2023 report from the Office of Cannabis Policy, which indicated that around 45% of cannabis in Maine’s medical market would fail to meet recreational standards. Additionally, concerns arose over illegal growers allegedly linked to organized crime, flooding the market with low-cost cannabis, further complicating the landscape for legal providers.
During public hearings, numerous medical cannabis caregivers and consumers voiced their opposition to the proposed bills, submitting nearly 1,000 pieces of written testimony. They challenged the effectiveness of the existing testing protocols within the recreational market, citing several recalls that raised doubts about the reliability of the state’s testing standards.
The medical cannabis sector in Maine has faced numerous challenges, including an oversaturated market and increasing competition from recreational cannabis sales. In 2023, the medical market generated approximately $280 million in revenue, a decline from $371 million in 2021, while the recreational market brought in $217 million. The number of licensed medical cannabis providers, known as caregivers, has halved since 2016, dropping from 3,257 to 1,627 as of May 2023.
Belcher described the current situation as a struggle for survival for many providers in the industry.
In addition to the testing bills, lawmakers carried over several other proposals, including a measure that would require legislative confirmation for the director of the Office of Cannabis Policy, instead of allowing appointment by the commissioner of the Department of Administrative and Financial Services. Another proposal regarding cannabis social clubs and public consumption was also postponed for further review. Earlier sessions saw the defeat of two bills aimed at implementing revenue-sharing for municipalities allowing recreational cannabis businesses.
As the debate continues, Maine’s medical cannabis providers remain vigilant, preparing for upcoming legislative sessions that may revisit testing and other regulatory measures.
Czech 
English 
Spanish 
German